Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Denmark: COPSAC, Copenhagen Prospective Study of Childhood Asthma, researchers in Copenhagen, Denmark, noted that a higher risk...
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
GLP-1 Receptor antagonists used in a study allay fears about thyroid cancer.
2.
In breast-conserving surgery, is micro-CT a useful tool for determining tumor margins?
3.
Risk of a Second Primary Melanoma Similar Regardless of Race/Ethnicity
4.
Imetelstat for MDS-relateret anemia er godkendt af Food and Drug Administrations panel.
5.
Opposition to the Surgical Lymph Node Sampling Rule for Lung Resection.
1.
Understanding Adenomyosis: The Role of Ultrasound in Diagnosis Introduction
2.
Tumor Evolution: Signaling, Cancer Cell Plasticity, and Intratumor Heterogeneity
3.
Circulating Tumor Cells & Platelet Interactions: Crosstalk for Therapeutic Advances
4.
Cancer Trials 2025: Vaccines, Metabolic Targets, and the Microbiome in Oncology
5.
Unveiling the Mystery Behind Castleman Disease – Understanding Its Causes and Symptoms
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
2.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
3.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
4.
Current Scenario of Cancer- Q&A Session to Close the Gap
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge